Cancer Letters Response to Reviewers: How to Write a Rebuttal That Wins (2026)
How to write a point-by-point response to reviewers for Cancer Letters, where a major revision means functional and in vivo validation, not a descriptive rewrite. Grounded in pre-submission review work on Cancer Letters manuscripts.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How to use this page well
These pages work best when they behave like tools, not essays. Use the quick structure first, then apply it to the exact journal and manuscript situation.
Question | What to do |
|---|---|
Use this page for | Building a point-by-point response that is easy for reviewers and editors to trust. |
Start with | State the reviewer concern clearly, then pair each response with the exact evidence or revision. |
Common mistake | Sounding defensive or abstract instead of specific about what changed. |
Best next step | Turn the response into a visible checklist or matrix before you finalize the letter. |
Quick answer: A Cancer Letters response to reviewers is a point-by-point rebuttal that treats a major revision as a request for new functional and in vivo data, not a descriptive rewrite.
Open with a short letter to the handling editor, then for each comment specify the exact page and line number plus the new figure panel that you cite for every change, answer under Reviewer 1 and Reviewer 2, and answer a mechanism request with a rescue or knockdown experiment rather than more correlative expression plots. Cancer Letters reviewers apply a mechanistic-depth and translational-relevance bar, so the data, not the prose, decide the round.
Last reviewed June 7, 2026.
Start with the Cancer Letters rebuttal readiness check before you submit, or work through this guide by hand. For broader cluster context, see the Cancer Letters submission guide and the oncology cancer journal hub.
How this guide was produced. We reviewed Elsevier's published author and peer-review guidance for Cancer Letters, checked the journal's stated scope in basic and translational oncology, and cross-referenced the patterns we see in our own pre-submission review corpus of Cancer Letters-targeted manuscripts. Every rebuttal pattern below is evidence-first, not generic advice.
What does a Cancer Letters response to reviewers require?
The Manusights Cancer Letters rebuttal scan. This guide tells you what the handling editor and the two to three reviewers look for in a Cancer Letters rebuttal. The scan tells you whether YOUR response letter passes that check before you upload it to Editorial Manager. In our pre-submission review work with Cancer Letters manuscripts, the rebuttals that clear one round answer functional-validation requests with functional data; the patterns below are the same ones the mechanistic cancer-biology referee flags at re-review. We do not train AI on your manuscript and delete it within 24 hours.
Three things make a Cancer Letters rebuttal different from a generic one. First, the bar is mechanistic depth with translational relevance: Cancer Letters (Elsevier Ireland, published since 1975, ISSN 0304-3835) covers basic and translational oncology, and its reviewers want a result that establishes causality and connects to clinical bearing, not a descriptive snapshot.
Second, a major revision usually means new experiments such as a rescue, a knockdown or knockout, a second cell-line replicate, or an in vivo model, not a wording pass. Third, the review is single-blind with typically two to three reviewers, often a mechanistic cancer-biology expert plus an application-domain specialist, so your causal claim has to satisfy the referee whose entire job is to test it.
The journal also charges an open-access APC in the high-three-thousand-dollar range, a sunk-cost reason to get the revision right the first time rather than risk a rejection on revision.
Element | What Cancer Letters expects | What reviewers flag at re-review |
|---|---|---|
Mechanism | Causality shown by a functional experiment | More correlative expression data for a causality question |
Validation | Rescue, knockdown, knockout, or second cell line | A single cell line and a hedge in the Discussion |
Translational reach | In vivo model or patient-sample correlation | A cell-line-only result called clinically relevant |
Structure | Editor letter, then point-by-point per reviewer | Free-form prose answering all comments together |
Specificity | Page and line number plus new figure panel | "We have updated the manuscript" with no location |
Tone | Substantive on science, gracious on style | Defensive on every minor stylistic suggestion |
Source: Elsevier author and peer-review guidance for Cancer Letters and the journal's stated scope, accessed June 2026.
The copyable Cancer Letters rebuttal template
Cancer Letters reviewers re-check your revision against the comments they raised, so a clean, scannable structure does real work. Copy this skeleton, then replace the bracketed text with your own changes. Keep the reviewer text and your reply in two distinct fonts or colors.
Dear Editor,
Thank you for the opportunity to revise our manuscript the manuscript title
(CANLET-[ID]). We are grateful to the reviewers for their careful
reports. In response, we have added [new in vivo / rescue / knockdown
experiment], repeated the key result in a second cell line, revised
Figure [N], and clarified the [methods / statistics] section. A
point-by-point response follows; reviewer comments are in bold and our
replies in plain text, with revised-manuscript page and line numbers
plus the new figure panel given for every change.
----------------------------------------------------------------
Reviewer 1
Comment 1.1: "The causal role of [gene] is not established; the data
are correlative."
Response: We agree. We have added a rescue experiment (new Figure 3d):
re-expression of [gene] in the knockdown background restored
[phenotype]. The functional result is described on page 9, lines 4 to
15.
Comment 1.2: "The finding rests on a single cell line."
Response: We have repeated the core experiment in [second cell line]
(new Figure 2e to 2g); the effect is consistent. See page 7, lines 18
to 24, and Supplementary Figure 4.
----------------------------------------------------------------
Reviewer 2
Comment 2.1: "The translational relevance is asserted but not shown."
Response: We have added an orthotopic xenograft model (new Figure 5a
to 5c) showing reduced tumor growth, and a TCGA correlation
(Supplementary Figure 6). Revised text is on page 13, lines 2 to 11.
Comment 2.2: "The statistics for the survival analysis are unclear."
Response: We have clarified that n = [N] per group and added the test
and effect size to the Methods. See page 16, lines 7 to 13.
We believe the revised manuscript now establishes causality and
translational relevance, and we look forward to your decision.
Sincerely,
[Corresponding author, on behalf of all authors]The template carries the four tokens that reviewers actually scan for: a letter to the editor, a Reviewer 1 / Reviewer 2 structure, explicit action language ("we have added", "we have repeated", "we have clarified"), and a page and line reference plus a new figure panel for every change.
The page-and-line rule: cite the location of every change
State the exact page and line number for each manuscript revision, and reference the specific new figure panel, table, or supplementary file you added. This is the single most-cited rebuttal failure at Cancer Letters and across Elsevier oncology titles. A reviewer who has to hunt for your new in vivo figure reads it as evasion.
A reviewer who can click straight to page 9, lines 4 to 15, and new Figure 3d, and see the rescue result, finishes faster and re-reviews more favorably. Never write "we have addressed this in the manuscript" without a location. Use the line numbers from the revised file, not the original, and name the new figure panel, because at Cancer Letters the new data are the whole point of the revision.
Reviewer-text vs author-response typography
Make the reviewer's words and your reply visually distinct. Put each reviewer comment in bold or a colored text box, and keep your response in plain regular text directly beneath it. The handling editor and both reviewers scan dozens of these letters; a rebuttal where comment and reply blur together costs you attention you need.
The distinction is not cosmetic at Cancer Letters specifically, because the mechanistic cancer-biology referee is reading to confirm one thing, that the causal claim is now supported by a functional experiment, and a clean two-font or two-color layout lets them find that answer in seconds instead of giving up and asking for another round.
Tone calibration: how to phrase the hard replies
The same reviewers who raised the comments read your tone across every reply. A defensive answer to the mechanism request is exactly the one that triggers a rejection on revision. Calibrate.
Bad (defensive or vague) | Better (substantive and gracious) |
|---|---|
"The reviewer has misunderstood our mechanism." | "We did not establish the mechanism clearly; we have added a rescue experiment (new Figure 3d, page 9) that demonstrates the causal role directly." |
"An in vivo model is outside the scope of this study." | "We agree this would strengthen the translational claim. We have added an orthotopic xenograft (new Figure 5a to 5c) and, where the full model was not feasible, bounded the claim accordingly in the Discussion." |
"We have addressed this concern in the text." | "We have repeated the result in a second cell line (new Figure 2e to 2g, page 7, lines 18 to 24)." |
"The expression data already support our claim." | "Expression data alone are correlative; we have added the knockdown-plus-rescue experiment the reviewer requested (new Figure 3d) to establish causality." |
"Our finding is obviously clinically relevant." | "We have added a patient-sample correlation (Supplementary Figure 6) and an in vivo result (new Figure 5) to support the translational claim." |
The pattern that works: concede where the reviewer is right, run the functional or in vivo experiment, point to the exact new figure and line, and push back only on a request that is genuinely out of scope, with a reason and the strongest in-scope alternative.
The Cancer Letters reviewer culture you are writing into
Cancer Letters runs single-blind peer review with typically two to three reviewers, and the composition matters: the journal usually pairs a mechanistic cancer-biology expert with an application-domain or translational specialist. That pairing is why the journal's revision bar is what it is. The mechanism reviewer is testing whether your causal claim survives a functional experiment; the translational reviewer is testing whether the result has clinical bearing. A rebuttal that satisfies one and ignores the other stalls.
The defining feature is the mechanistic-depth and translational-relevance bar that drives most major revisions. Cancer Letters has a stated emphasis on basic and translational oncology, including molecular and cell biology of cancer, metastasis, the tumor microenvironment, drug resistance, and experimental therapeutics. In practice, the reviewers read a manuscript and ask: is this causal, or correlative? Is this one cell line, or is it reproducible? Does this connect to the clinic, or stop at a dish?
A major revision is the editor's way of saying the science is interesting but the evidence has not crossed those lines yet.
This is why the journal is hostile to descriptive single-cell-line studies. A paper that reports a gene is up in tumors, knocks it down in one line, sees a phenotype, and stops, is the archetypal Cancer Letters major revision. The reviewers will ask for a rescue to prove the phenotype is on-target, a second cell line to prove it is not an artifact, and an in vivo or patient-sample result to prove it matters. Your rebuttal has to deliver those, not argue around them.
How this compares to the field matters for calibration. A descriptive observation that might clear a lower-tier oncology journal with a clarification will not clear Cancer Letters, because the mechanism referee is specifically there to demand causality. Cancer Letters sits below the Cancer Cell and Nature flagship novelty bar but well above a generic society journal: it wants rigorous mechanism plus a credible translational thread, and it will hold a revision until both are shown.
Writing a Cancer Letters rebuttal as if clarification will satisfy a mechanism reviewer is the most expensive misread an author can make.
SciRev and LetPub community data put the typical peer-review round at roughly 2.7 months, which sets your planning clock: the in vivo or rescue experiment a major revision asks for is often the rate-limiting step, so start it the day the decision lands.
Key Insight
At Cancer Letters, a major revision is a request for new functional and in vivo data, not better prose. The mechanism reviewer is reading your rebuttal to confirm one thing: that your causal claim is now backed by a rescue, a knockdown, or an in vivo result. Answer that question with an experiment, or expect a second round.
What our Cancer Letters rebuttal reviews surface
In our pre-submission review work with Cancer Letters manuscripts, the rebuttals that stall in a second revision round share a small set of recurring weaknesses. These are the same ones the mechanistic cancer-biology referee flags at re-review, and each maps to a specific, named failure pattern you can test against your own draft response before you upload it.
Answering a mechanism request with more correlative expression data. The most common and most expensive pattern in our Cancer Letters pre-submission reviews is a rebuttal that meets a "show causality" comment by adding another expression panel, another correlation, or another bar chart of the same descriptive kind.
A causality question at Cancer Letters is answered by a rescue experiment, a knockdown or knockout, or a perturbation that moves the phenotype in the predicted direction, not by more of the data that prompted the question. Across our Cancer Letters rebuttal reviews, this mismatch is the single strongest predictor of a rejection on revision.
Missing the in vivo or rescue experiment the reviewer requested. When a Cancer Letters reviewer asks for an in vivo model, an orthotopic xenograft, or a rescue, and the author returns text instead, the revision fails on the exact axis the journal cares about.
In our pre-submission reviews of Cancer Letters submissions, responses that substitute a Discussion paragraph for a requested functional experiment draw a re-review comment that says, in effect, you did not do what we asked. If the experiment is genuinely infeasible, the rebuttal has to say so explicitly, propose the strongest in-scope control or alternative, and bound the claim accordingly, not quietly skip it.
A revision that stays descriptive. Some rebuttals add new panels but never cross from observation to mechanism: a second figure of the same correlative type, a longer results narrative, a richer methods section, all without a functional or in vivo result. In our pre-submission review work with Cancer Letters manuscripts, a revision that stays descriptive is read as the author not understanding the bar, which is worse than a thin first submission.
The fix is one well-designed functional experiment, documented to its new figure panel, that converts the central correlation into a causal claim.
Inconsistent answers across reviewers. Because the mechanism reviewer and the translational reviewer often raise overlapping points, a rebuttal that frames the same statistical analysis or sample size one way for Reviewer 1 and another for Reviewer 2 reads as evasive. In our Cancer Letters pre-submission reviews we routinely find a reproducibility or controls concern raised by two reviewers and answered with two different justifications. Reconcile every overlapping comment to a single, consistent answer before submission.
Run the functional experiment, document its figure and location, bound any claim you cannot fully validate, and reconcile across reviewers. That discipline is what separates a Cancer Letters rebuttal that clears one revision round from one that stalls into a rejection. Check your Cancer Letters point-by-point response for these patterns before you submit.
Readiness check
Run the scan to see how your manuscript scores on these criteria.
See score, top issues, and what to fix before you submit.
When to comply and when to push back
Situation | Recommended approach at Cancer Letters |
|---|---|
Reviewer asks for a rescue to prove causality | Comply. Run the knockdown-plus-rescue; it is the highest-leverage fix. Cite the new figure panel. |
Reviewer flags a single cell line | Comply. Repeat the core result in a second line; one replicate rarely satisfies the mechanism referee. |
Reviewer requests an in vivo model | Comply where feasible. If genuinely impossible, propose the strongest in-scope alternative and bound the translational claim. |
Reviewer questions sample size or statistics | Comply. Add the test, the n per group, and the effect size to Methods. |
Reviewer asks for a patient-sample or clinical correlation | Comply with a public-dataset correlation if you lack samples; it strengthens the translational thread Cancer Letters wants. |
Reviewer requests an experiment genuinely outside the model system | Push back with a reason, add the closest feasible validation, note the open question in the Discussion. |
Source: Manusights pre-submission reviews of Cancer Letters-targeted resubmissions, 2025 cohort.
How much work a Cancer Letters rebuttal actually takes
Authors consistently underestimate the new-data effort and overestimate the writing effort. This breakdown is about workload, not the journal's decision clock; for the end-to-end schedule, see the Cancer Letters submission guide.
Rebuttal task | Where the effort goes | What it costs you |
|---|---|---|
Reading and clustering reviewer reports | Finding the one causality concern behind the comments | A day of careful reading, not a skim |
Running the rescue or in vivo experiment | The actual bar for a major revision | The bulk of the work, often several weeks of bench or animal time |
Repeating the key result in a second cell line | Proving the effect is not a line-specific artifact | Real time, but cheaper than a rejection on revision |
Writing the point-by-point replies | One reply plus a figure panel and line reference per comment | Less than authors fear once the data exist |
Reconciling overlapping comments | Same answer for the mechanism and translational reviewers | Skipped most often, and it shows |
Source: Manusights pre-submission reviews of Cancer Letters resubmissions, 2025 cohort, last updated June 7, 2026.
Honest friction: rejection on revision is real
A major-revision invitation at Cancer Letters is not a soft acceptance. The revised manuscript and your point-by-point response go back to the original reviewers, including the mechanistic cancer-biology referee, and the paper can still end in rejection after re-review if the new data do not establish causality and translational relevance.
The journal's acceptance rate sits in the low twenties, and a meaningful share of the rejection decisions land at the revision stage, which tells you Cancer Letters does not rubber-stamp revisions. Most rejections on revision trace to one cause: the author answered a functional-validation request with descriptive data.
Think twice before you resubmit if any of these are true. The response answers a "show causality" comment with another correlation. A reviewer asked for an in vivo model and you returned a Discussion paragraph. The revision adds panels but never crosses from observation to mechanism. The same reproducibility concern from two reviewers got two different answers. Fixing these before resubmission is what keeps a major revision from becoming a rejection.
Red flags a Cancer Letters reviewer spots in seconds
Before you upload, scan your own rebuttal for the patterns that draw an immediate re-review comment. Each is a specific, checkable thing in your draft, not a vague quality dimension.
- A causality reply with no new functional figure. Any answer to a "show mechanism" comment that points only to expression data or text reads as not having done the experiment.
- Text where an in vivo model was requested. A reviewer asked for a xenograft or rescue and the reply only adds a sentence to the Discussion.
This is the most common cause of a rejection on revision.
- A single cell line, still. If the core result rests on one line after revision, the mechanism referee will not assume reproducibility.
- Two answers to one shared point. The same controls or sample-size concern raised by both reviewers, answered two different ways, signals you did not reconcile the reports.
How does this guide go beyond the Cancer Letters author guidelines?
The official Elsevier guidance tells you to submit a point-by-point response and to explain the relationship between the revised and previous submission.
It does not tell you that the revision bar is mechanistic causality plus translational relevance, that the mechanism reviewer is specifically there to demand a functional experiment, that a descriptive single-cell-line revision will not clear re-review, or that an in vivo model is often the rate-limiting step you should start the day the decision lands. Those facts change how you write every reply.
The patterns above come from our pre-submission reviews of Cancer Letters manuscripts, and they are testable against your own draft today, not theoretical concerns.
- Manusights pre-submission reviews of Cancer Letters-targeted manuscripts (2025 cohort)
Frequently asked questions
New functional or in vivo data, not a rewrite. Cancer Letters reviewers apply a mechanistic-depth and translational-relevance bar, so a major-revision request typically asks for the rescue experiment, the knockdown or knockout, a second cell-line replicate, or an in vivo model that the first submission lacked. A revision that answers a mechanism request with more correlative expression data is the single most common reason a Cancer Letters paper stalls into a second round or a rejection on revision.
Open with a short letter to the handling editor summarizing the new experiments, then answer each comment in order under Reviewer 1 and Reviewer 2, quote the reviewer text in full, state the exact change, and give the page and line number in the revised manuscript plus the new figure panel. Keep reviewer text and your reply in two distinct fonts or colors so the editor and the second-round reviewers can scan it fast.
Often, yes, when the claim is about tumor growth, metastasis, or therapy response. Cancer Letters emphasizes translational relevance, and reviewers frequently ask for an orthotopic or xenograft model, or a patient-sample correlation, to move a finding from a cell-line observation to a result with clinical bearing. If you genuinely cannot run the in vivo model, propose the strongest in-scope alternative and bound the claim accordingly rather than ignoring the request.
Yes. A major-revision invitation is not an acceptance. The revised manuscript and your point-by-point response go back to the original reviewers, including the mechanistic cancer-biology referee, and the paper can be rejected after re-review if the new data do not establish causality or translational relevance. Most rejections on revision trace to one cause: the author answered a functional-validation request with descriptive data.
Cancer Letters runs single-blind review with typically two to three reviewers, often a mechanistic cancer-biology expert plus an application-domain specialist. Your rebuttal goes to the same reviewers who raised the comments, so keep every overlapping reply consistent and make sure the mechanism reviewer can see that the causal claim is now supported by a functional experiment.
Sources
- Cancer Letters journal home, ScienceDirect (Elsevier) (accessed June 2026)
- Guide for authors, Cancer Letters, ScienceDirect (Elsevier) (accessed June 2026)
- Cancer Letters journal selector profile, LetPub (accessed June 2026)
- Ten simple rules for writing a response to reviewers, William Stafford Noble, PLOS Computational Biology (accessed June 2026)
Final step
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan. See score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Find out if this manuscript is ready to submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.